

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION
(Rule 14a-101)**

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

AVADEL PHARMACEUTICALS PLC
(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.

 - Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies: _____
 - (2) Aggregate number of securities to which transaction applies: _____
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): _____
 - (4) Proposed maximum aggregate value of transaction: _____
 - (5) Total fee paid: _____

 - Fee paid previously with preliminary materials.

 - Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid: _____
 - (2) Form, Schedule or Registration Statement No.: _____
 - (3) Filing Party: _____
 - (4) Date Filed: _____
-



MR SAM SAMPLE
DESIGNATION (IF ANY)
MR JOINT HOLDER 1
ADD1
ADD2
ADD3
ADD4



100000

AVADEL PLC

Meeting Information

Meeting Type:	Annual Meeting
For holders as of:	May 25, 2021
Meeting Date:	August 3, 2021
Meeting Time:	10:00 AM (Irish Standard Time)
Location:	Arthur Cox Ten Earlsfort Terrace Dublin 2, D02 T380, IRELAND

You are receiving this communication because you are a registered holder of ordinary shares of Avadel Pharmaceuticals plc.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.eproxyappointment.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

Shareholder Reference Number:	<input type="text" value="C1234567890"/>
Control Number:	<input type="text" value="917202"/>
PIN#:	<input type="text" value="1234"/>

00000000000000000000

12057C 012

Before You Vote

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

1. Notice of Annual General Meeting & Proxy Statement
2. Annual Report on Form 10-K
3. Irish Statutory Financial Statements, including Related Reports

How to View Online:

Have the information that is printed in the box (located on the previous page) and visit: www.eproxyappointment.com

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

- 1) **BY INTERNET:** www.eproxyappointment.com
- 2) **BY TELEPHONE:** Ireland: +353 1 216 3100
France: +33 (0)472-783-434
United States: +1 (636) 449-1830
- 3) **BY E-MAIL*:** usservices@computershare.ie

*If requesting materials by e-mail, please send an e-mail with the information that is printed in the box on the previous page along with the company name Avadel Pharmaceuticals plc in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will **NOT** be forwarded to your investment advisor. Please make the request as instructed above on or before July 27, 2021 to facilitate timely delivery.

How to Vote

Please Choose One of the Following Voting Methods

Vote In Person: If you choose to vote these shares in person at the meeting, please check the meeting materials for any special requirements for meeting attendance.

Vote By Internet: To vote now by Internet, go to www.eproxyappointment.com. Have the information that is printed in the box marked on the previous page and follow the instructions.

Vote By Mail or E-Mail: You can vote by mail or e-mail by requesting a paper copy of the materials, which will include a proxy card and instructions for submission.

Voting Items

The Board of Directors recommends a vote FOR the nominees listed under item 1:

1. Election of Directors

Nominees:

- 1a. Gregory J. Divis
- 1b. Dr. Eric J. Ende
- 1c. Geoffrey M. Glass
- 1d. Dr. Mark A. McCamish
- 1e. Linda S. Palczuk
- 1f. Peter J. Thornton

The Board of Directors recommends a vote FOR the following proposals:

- 2. To ratify, in a non-binding vote, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the Audit Committee of the Board to set the independent registered public auditor and accounting firm remuneration.
- 3. To renew the Board of Directors' existing authority under Irish law to allot and issue ordinary shares.
- 4. To approve any motion to adjourn the Annual General Meeting of Shareholders, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting of Shareholders to approve any or all of Proposal 5.

Special Resolution.

- 5. To renew the Board of Directors' existing authority under Irish law to opt-out of the statutory pre-emption rights.

NOTE: The Board of Directors will consider and act upon any other business as may properly come before the meeting or any adjournment or postponement thereof.